Role of Interleukin-1 (IL-1) in the Pathogenesis of Systemic Onset Juvenile Idiopathic Arthritis and Clinical Response to IL-1 Blockade

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2005 Apr 27

PMID 15851489

Citations 349

Authors

Virginia Pascual

Florence Allantaz

Edsel Arce

Marilynn Punaro

Jacques Banchereau

Affiliations

Soon will be listed here.

Abstract

Systemic onset juvenile idiopathic arthritis (SoJIA) encompasses approximately 10% of cases of arthritis that begin in childhood. The disease is unique in terms of clinical manifestations, severity of joint involvement, and lack of response to tumor necrosis factor blockade. Here, we show that serum from SoJIA patients induces the transcription of innate immunity genes, including interleukin (IL)-1 in healthy peripheral blood mononuclear cells (PBMCs). Upon activation, SoJIA PBMCs release large amounts of IL-1beta. We administered recombinant IL-1 receptor antagonist to nine SoJIA patients who were refractory to other therapies. Complete remission was obtained in seven out of nine patients and a partial response was obtained in the other two patients. We conclude that IL-1 is a major mediator of the inflammatory cascade that underlies SoJIA and that this cytokine represents a target for therapy in this disease.

Citing Articles

Romano F, Di Scipio F, Baima G, Franco F, Aimetti M, Berta G J Clin Med. 2025; 14(1.

PMID: 39797336 PMC: 11721659. DOI: 10.3390/jcm14010254.

Comprehensive Characterization of Th2/Th17 Cells-Related Gene in Systemic Juvenile Rheumatoid Arthritis: Evidence from Mendelian Randomization and Transcriptome Data Using Multiple Machine Learning Approaches.

Wang M, Wang J, Lv F, Song A, Bao W, Li H Int J Gen Med. 2024; 17:5973-5996.

PMID: 39678686 PMC: 11645899. DOI: 10.2147/IJGM.S482288.

Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.

Wu Y, Sun X, Kang K, Yang Y, Li H, Zhao A J Hematol Oncol. 2024; 17(1):106.

PMID: 39511607 PMC: 11542428. DOI: 10.1186/s13045-024-01621-x.

Evolution of treatment options for juvenile idiopathic arthritis.

Ren T, Guan J, Li Y, Li N, Li Z World J Orthop. 2024; 15(9):831-835.

PMID: 39318493 PMC: 11417629. DOI: 10.5312/wjo.v15.i9.831.

Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.

Bindoli S, De Matteis A, Mitrovic S, Fautrel B, Carmona L, De Benedetti F Ann Rheum Dis. 2024; 83(12):1731-1747.

PMID: 39317415 PMC: 11671904. DOI: 10.1136/ard-2024-225854.

References

Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A . Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 2000; 191(2):313-20. PMC: 2195765. DOI: 10.1084/jem.191.2.313. View

Genovese M, Cohen S, Moreland L, Lium D, Robbins S, Newmark R . Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004; 50(5):1412-9. DOI: 10.1002/art.20221. View

Lomater C, Gerloni V, Gattinara M, MAZZOTTI J, Cimaz R, Fantini F . Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000; 27(2):491-6. View

Lovell D, Giannini E, Reiff A, Cawkwell G, Silverman E, Nocton J . Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000; 342(11):763-9. DOI: 10.1056/NEJM200003163421103. View

Spiegel L, Schneider R, LANG B, Birdi N, Silverman E, Laxer R . Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 2000; 43(11):2402-9. DOI: 10.1002/1529-0131(200011)43:11<2402::AID-ANR5>3.0.CO;2-C. View

Lehman T . Clinical trials for the treatment of systemic onset juvenile rheumatoid arthritis-juvenile idiopathic arthritis. Curr Rheumatol Rep. 2000; 2(4):313-5. DOI: 10.1007/s11926-000-0068-9. View

Modesto C, Woo P, Garcia-Consuegra J, Merino R, Garcia-Granero M, Arnal C . Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for a bad prognosis. Clin Exp Rheumatol. 2001; 19(2):211-7. View

Blanco P, Palucka A, Gill M, Pascual V, Banchereau J . Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001; 294(5546):1540-3. DOI: 10.1126/science.1064890. View

Lehman T, Striegel K, Onel K . Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr. 2002; 140(1):125-7. DOI: 10.1067/mpd.2002.120835. View

10.

Saijo S, Asano M, Horai R, Yamamoto H, Iwakura Y . Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum. 2002; 46(2):533-44. DOI: 10.1002/art.10172. View

11.

Muzaffer M, Dayer J, Feldman B, Pruzanski W, Roux-Lombard P, Schneider R . Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. J Rheumatol. 2002; 29(5):1071-8. View

12.

Aksentijevich I, Nowak M, Mallah M, Chae J, Watford W, Hofmann S . De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002; 46(12):3340-8. PMC: 4556432. DOI: 10.1002/art.10688. View

13.

Lovell D, Giannini E, Reiff A, Jones O, Schneider R, Olson J . Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003; 48(1):218-26. DOI: 10.1002/art.10710. View

14.

Bowyer S, Roettcher P, Higgins G, Adams B, Myers L, Wallace C . Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol. 2003; 30(2):394-400. View

15.

Bennett L, Palucka A, Arce E, Cantrell V, Borvak J, Banchereau J . Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003; 197(6):711-23. PMC: 2193846. DOI: 10.1084/jem.20021553. View

16.

Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M . Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003; 48(4):1093-101. DOI: 10.1002/art.10885. View

17.

Saeki T, Naya A . CCR1 chemokine receptor antagonist. Curr Pharm Des. 2003; 9(15):1201-8. DOI: 10.2174/1381612033454937. View

18.

Shoham N, Centola M, Mansfield E, Hull K, Wood G, Wise C . Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A. 2003; 100(23):13501-6. PMC: 263843. DOI: 10.1073/pnas.2135380100. View

19.

Hawkins P, Lachmann H, Aganna E, McDermott M . Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 2004; 50(2):607-12. DOI: 10.1002/art.20033. View

20.

Ravelli A, Martini A . Early predictors of outcome in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004; 21(5 Suppl 31):S89-93. View